Abstract
Leukotrienes are important mediators of pain and inflammation and they are produced in the arachidonic acid pathway via 5-lipoxygenase. They have been shown to have important roles in pyresis following antigen attack and in aspirin- intolerant asthma. They promote inflammation processes including eosinophil migration, increase in vascular permeability and bronchoconstriction. Hence, targeting the enzymes involved in the synthesis of these mediators can lead to the development of novel anti-inflammatory drugs. However, no drugs have yet been developed targeting leukotriene C4 synthase, a key enzyme leading to the synthesis of cysteinyl leukotrienes. The recent elucidation of its crystal structure now opens up the possibility of drugs against it. The inhibitors developed for this enzyme until now and the structural features responsible for their activity are discussed in this review. This understanding could lead to the design of new chemical entities.
Keywords: Asthma, anti-inflammatory drugs, inflammation, inhibitors, leukotriene C4 synthase, 5-lipoxygenase, antigen attack, cysteinyl leukotrienes, bronchoconstriction, prostaglandins
Current Drug Targets
Title:Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Volume: 13 Issue: 8
Author(s): Nisha S. Devi and Mukesh Doble
Affiliation:
Keywords: Asthma, anti-inflammatory drugs, inflammation, inhibitors, leukotriene C4 synthase, 5-lipoxygenase, antigen attack, cysteinyl leukotrienes, bronchoconstriction, prostaglandins
Abstract: Leukotrienes are important mediators of pain and inflammation and they are produced in the arachidonic acid pathway via 5-lipoxygenase. They have been shown to have important roles in pyresis following antigen attack and in aspirin- intolerant asthma. They promote inflammation processes including eosinophil migration, increase in vascular permeability and bronchoconstriction. Hence, targeting the enzymes involved in the synthesis of these mediators can lead to the development of novel anti-inflammatory drugs. However, no drugs have yet been developed targeting leukotriene C4 synthase, a key enzyme leading to the synthesis of cysteinyl leukotrienes. The recent elucidation of its crystal structure now opens up the possibility of drugs against it. The inhibitors developed for this enzyme until now and the structural features responsible for their activity are discussed in this review. This understanding could lead to the design of new chemical entities.
Export Options
About this article
Cite this article as:
S. Devi Nisha and Doble Mukesh, Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation, Current Drug Targets 2012; 13 (8) . https://dx.doi.org/10.2174/138945012802009053
DOI https://dx.doi.org/10.2174/138945012802009053 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics in the Americas: The Impact of Genetic Admixture
Current Drug Targets The Application of Phage Display in Allergy Research: Characterization of IgE, Identification of Allergens and Development of Novel Therapeutics
Current Pharmaceutical Biotechnology The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Childhood Hospitalisations for Physical Disease and Risk of Mental Disorders During Adolescence and Early Adulthood
Adolescent Psychiatry Enzyme Inhibitors
Current Bioactive Compounds Alpinia calcarata Roscoe: A Rich Source of Phytopharmaceuticals in Sri Lanka
The Natural Products Journal Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches
Current Medicinal Chemistry Colon as Target for Drug Delivery
Current Drug Therapy Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Prediction of Comparative Inhibition Efficiency for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Divergent Roles of IRS (Insulin Receptor Substrate) 1 and 2 in Liver and Skeletal Muscle
Current Medicinal Chemistry Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology Drug Design Benefits from Molecular Dynamics: Some Examples
Current Computer-Aided Drug Design Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design Matrix Metalloproteinase-9 and Airway Remodeling in Asthma
Current Drug Targets - Inflammation & Allergy